The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
SEQUOIA trial investigators compared pegilodecakin plus FOLFOX with FOLFOX alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Investigators tested the hypothesis that greater exposure to light at night (LAN) is associated with an increased risk for thyroid cancer by studying artificial outdoor LAN measured by satellite imagery in relation to thyroid cancer.
Positive association mainly driven by incidence of papillary thyroid cancer.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.